Company intelligence / Profile preview

Zephyr Sleep Technologies

Calgary, Alberta, Canadasleepreviewmag.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Zephyr Sleep Technologies developed the first FDA-cleared at-home device—MATRx plus—for identifying patients with obstructive sleep apnea who would benefit from oral appliance therapy. The technology was validated through three clinical studies involving over 280 patients. Despite commercial launch in North America and partnerships with major dental companies, operations ceased in June 2021 after unsuccessful fundraising during the COVID pandemic.

Therapeutic areas: Pulmonology
Modalities: DeviceNon-pharmacological therapy (oral appliance therapy)
Industry: Physiological Monitoring

Partnerships

Dentsply Sirona (distribution/market entry partnership for US market)ProSomnus Sleep Technologies (co-marketing/sales partnership on OSA products)

Beyond the preview

Go deeper on Zephyr Sleep Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zephyr Sleep Technologies.

Explore the full profile